Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCERTO: Tacrolimus MR Conversion in Kidney Transplant
NCT00481481Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2007
- Primary completion
- Apr 2009
- Modality
- RNA-Targeting Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of tacrolimus in kidney transplant rejection, sponsored by Astellas Pharma. Primary endpoint: Change in creatinine clearance at 24 weeks. Started Apr 2007; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00481481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00481481.